Analysts’ Weekly Ratings Updates for First Tracks Biotherapeutics (TRAX)

First Tracks Biotherapeutics (NASDAQ: TRAX) recently received a number of ratings updates from brokerages and research firms:

• 8/13/2026 – First Tracks Biotherapeutics had its price target raised by Piper Sandler from $54.00 to $95.00. They now have an “overweight” rating on the stock.
• 8/13/2026 – First Tracks Biotherapeutics had its price target raised by HC Wainwright from $44.00 to $57.00. They now have a “buy” rating on the stock.
• 8/13/2026 – First Tracks Biotherapeutics had its price target raised by Barclays PLC from $48.00 to $65.00. They now have an “overweight” rating on the stock.
• 8/13/2026 – First Tracks Biotherapeutics had its price target raised by Wedbush from $60.00 to $70.00. They now have an “outperform” rating on the stock.
• 8/10/2026 – First Tracks Biotherapeutics had its price target raised by UBS Group AG from $45.00 to $65.00. They now have a “buy” rating on the stock.
• 7/28/2026 – First Tracks Biotherapeutics had its price target raised by Wells Fargo & Company from $30.00 to $55.00. They now have an “overweight” rating on the stock.
• 7/28/2026 – First Tracks Biotherapeutics had its price target raised by Wedbush from $30.00 to $60.00. They now have an “outperform” rating on the stock.
• 7/21/2026 – First Tracks Biotherapeutics had its price target raised by Barclays PLC from $40.00 to $48.00. They now have an “overweight” rating on the stock.
• 7/10/2026 – First Tracks Biotherapeutics had its price target raised by HC Wainwright from $30.00 to $44.00. They now have a “buy” rating on the stock.
• 7/8/2026 – First Tracks Biotherapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $30.00 price target on the stock.

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.